Christopher Di Simone
Impact in
- Obstetrics and Gynecology top 5%
- Endometrial and Cervical Cancer Treatments
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Renal cell carcinoma treatment 3
- Oncology 3
- Cancer Immunotherapy and Biomarkers 3
- Co-authors
- Michael J. Buchmeier (2 shared papers)Michelle Zandonatti (1 shared paper)Allen Lee Cohn (4 shared papers)Emmett V. Schmidt (3 shared papers)Perminder S. Sachdev (1 shared paper)Robert Shumaker (1 shared paper)Matthew Guo (1 shared paper)Daniel E. Stepan (1 shared paper)
- Journals
- Journal of Clinical Oncology (3 papers)Virology (3 papers)Journal for ImmunoTherapy of Cancer (1 paper)Hematological Oncology (1 paper)Annals of Oncology (1 paper)
- Partner nations
- United StatesUnited KingdomSpain
In The Last Decade
Christopher Di Simone
10 papers receiving 588 citations
Christopher Di Simone's Hit Papers
Peers
Comparison fields: 5 of 57
- Obstetrics and Gynecology 104
- Oncology 274
- Reproductive Medicine 72
- Infectious Diseases 135
- Immunology 113
Countries citing papers authored by Christopher Di Simone
This map shows the geographic impact of Christopher Di Simone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher Di Simone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher Di Simone more than expected).
Fields of papers citing papers by Christopher Di Simone
This network shows the impact of papers produced by Christopher Di Simone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher Di Simone. The network helps show where Christopher Di Simone may publish in the future.
Co-authors
The 25 scholars most cited alongside Christopher Di Simone, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial Hit paper breakdown → | 2019 | 360 |
| 2 | 1994 | 100 | |
| 3 | 1995 | 60 | |
| 4 | 2020 | 31 | |
| 5 | 2019 | 12 | |
| 6 | 1992 | 7 | |
| 7 | 2020 | 7 | |
| 8 | 2019 | 6 | |
| 9 | 2024 | 5 | |
| 10 | 2020 | 3 |
About Christopher Di Simone
Christopher Di Simone is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Epidemiology, Genetics and Molecular Biology, having authored 10 papers that have together received 591 indexed citations. Recurring topics across this work include Virus-based gene therapy research (3 papers), Renal cell carcinoma treatment (3 papers), Cancer Immunotherapy and Biomarkers (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Cytomegalovirus and herpesvirus research (2 papers), Chronic Myeloid Leukemia Treatments (2 papers), Renal and related cancers (2 papers) and Chronic Lymphocytic Leukemia Research (2 papers). The work is most often cited by research in Obstetrics and Gynecology (104 citations), Oncology (274 citations), Reproductive Medicine (72 citations), Infectious Diseases (135 citations) and Immunology (113 citations). Christopher Di Simone has collaborated with scholars based in United States, United Kingdom and Spain. Frequent co-authors include Michael J. Buchmeier, Michelle Zandonatti, Allen Lee Cohn, Emmett V. Schmidt, Perminder S. Sachdev, Robert Shumaker, Matthew Guo, Daniel E. Stepan, Nicholas J. Vogelzang and Matthew H. Taylor. Their work appears in journals such as Journal of Clinical Oncology, Virology, Journal for ImmunoTherapy of Cancer, Hematological Oncology and Annals of Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.